(BBH) VanEck Biotech - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US92189F7261 • Health
BBH: Biotechnology, Pharmaceuticals, Diagnostics, Therapeutics, Medical Devices
The VanEck Biotech ETF (NASDAQ: BBH) is designed to track the performance of companies in the biotechnology industry. The fund invests at least 80% of its total assets in securities that comprise its benchmark index, which includes common stocks and depositary receipts of U.S. exchange-listed biotechnology companies. These companies may include medium-capitalization firms and foreign entities listed on U.S. exchanges. The ETF is non-diversified, meaning it may concentrate its investments in a smaller number of securities. BBH provides exposure to a targeted segment of the healthcare sector, focusing on biotech innovation and research.
Ticker Symbol: BBH | Exchange: NASDAQ | Type: ETF | Country Origin: USA | ETF Category: Health. The fund is managed by VanEck and is available for investment through its website at http://www.vaneck.com.
Over the next three months, BBH is expected to trade within a range influenced by its technical indicators and fundamental trends. Based on its current price of 162.86, which is below its SMA20 (163.95) and SMA50 (161.54) but above its SMA200 (168.88), the ETF may experience short-term volatility as it tests these levels. The ATR of 2.20 suggests moderate price movement. Fundamentally, with an AUM of 396.75M USD, BBH maintains a stable investor base, but biotech sector performance is often sensitive to broader market conditions and regulatory developments.
Additional Sources for BBH ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BBH ETF Overview
| Market Cap in USD | 366m |
| Category | Health |
| TER | 0.35% |
| IPO / Inception | 2011-12-20 |
BBH ETF Ratings
| Growth Rating | -8.80 |
| Fundamental | - |
| Dividend Rating | 45.0 |
| Rel. Strength | -10.2 |
| Analysts | - |
| Fair Price Momentum | 134.61 USD |
| Fair Price DCF | - |
BBH Dividends
| Dividend Yield 12m | 0.80% |
| Yield on Cost 5y | 0.86% |
| Annual Growth 5y | 15.54% |
| Payout Consistency | 58.4% |
BBH Growth Ratios
| Growth Correlation 3m | -54.5% |
| Growth Correlation 12m | -35.9% |
| Growth Correlation 5y | -6.4% |
| CAGR 5y | 0.22% |
| CAGR/Max DD 5y | 0.01 |
| Sharpe Ratio 12m | 0.14 |
| Alpha | -10.74 |
| Beta | 0.840 |
| Volatility | 30.08% |
| Current Volume | 6.9k |
| Average Volume 20d | 9.2k |
As of April 16, 2025, the stock is trading at USD 147.74 with a total of 6,887 shares traded.
Over the past week, the price has changed by +5.45%, over one month by -10.10%, over three months by -7.36% and over the past year by -4.00%.
Neither. Based on ValueRay Analyses, VanEck Biotech is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -8.80 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBH as of April 2025 is 134.61. This means that BBH is currently overvalued and has a potential downside of -8.89%.
VanEck Biotech has no consensus analysts rating.
According to ValueRays Forecast Model, BBH VanEck Biotech will be worth about 148.8 in April 2026. The stock is currently trading at 147.74. This means that the stock has a potential upside of +0.68%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 148.8 | 0.7% |